Infliximab biosimilar CT-P13 in Crohn's disease

被引：2
|
作者：
Gecse, Krisztina B. [1 ]
D'Haens, Geert R. [1 ]
机构：
[1] Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Gastroenterol & Hepatol, NL-1105 AZ Amsterdam, Netherlands
来源：
LANCET | 2019年 / 393卷 / 10182期
关键词：
DOUBLE-BLIND; INNOVATOR INFLIXIMAB; PARALLEL-GROUP; EFFICACY; SAFETY;
D O I：
10.1016/S0140-6736(18)32778-8
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1671 / 1672
页数：2
相关论文
共 50 条
  • [1] Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis
    Keil, Radan
    Wasserbauer, Martin
    Zadorova, Zdena
    Hajer, Jan
    Drastich, Pavel
    Wohl, Pavel
    Benes, Marek
    Bojkova, Martina
    Svoboda, Pavel
    Konecny, Michal
    Falt, Premysl
    Vanasek, Tomas
    Pesta, Martin
    Pesek, Frantisek
    Bouchner, Ludek
    Kozeluhova, Jana
    Novotny, Ales
    Bartuskova, Lucie
    Spicak, Julius
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2016, 51 (09) : 1062 - 1068
  • [2] Infliximab biosimilar CT-P13 for inflammatory bowel disease
    Bonovas, Stefanos
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (06): : 373 - 375
  • [3] A Review of CT-P13: An Infliximab Biosimilar
    Kate McKeage
    [J]. BioDrugs, 2014, 28 : 313 - 321
  • [4] A Review of CT-P13: An Infliximab Biosimilar
    McKeage, Kate
    [J]. BIODRUGS, 2014, 28 (03) : 313 - 321
  • [5] COST-EFFECTIVENESS OF INFLIXIMAB'S BIOSIMILAR CT-P13 COMPARED TO INNOVATOR INFLIXIMAB FOR THE MANAGEMENT OF CROHN'S DISEASE.
    Beilman, Candace L.
    Ma, Christopher
    McCabe, Christopher
    Fedorak, Richard N.
    Halloran, Brendan P.
    [J]. GASTROENTEROLOGY, 2017, 152 (05) : S447 - S447
  • [6] CT-P13: a review on a biosimilar to infliximab in the treatment of inflammatory bowel disease
    Albshesh, Ahmad
    Ben-Horin, Shomron
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (10) : 971 - 978
  • [7] A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease
    Farkas, Klaudia
    Molnar, Tamas
    [J]. IMMUNOTHERAPY, 2018, 10 (02) : 107 - 117
  • [8] Biosimilar CT-P13 comparable to infliximab in active RA
    [J]. Nature Reviews Rheumatology, 2013, 9 (7) : 382 - 382
  • [9] CT-P13 biosimilar is non-inferior to infliximab
    Dickson I.
    [J]. Nature Reviews Gastroenterology & Hepatology, 2019, 16 (6) : 326 - 326
  • [10] Effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting in patients with Crohn's disease or ulcerative colitis
    Gheorghe, Cristian
    Svoboda, Pavel
    Mateescu, Bogdan
    [J]. JOURNAL OF DRUG ASSESSMENT, 2019, 8 (01) : 129 - 134
12345